Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients

被引:2
|
作者
Million, Matthieu [1 ,2 ]
Lagier, Jean-Christophe [1 ,2 ]
Hourdain, Jerome [3 ,4 ]
Franceschi, Frederic [3 ,4 ]
Deharo, Jean-Claude [3 ,4 ]
Parola, Philippe [1 ,5 ]
Brouqui, Philippe [1 ,2 ]
机构
[1] IHU Mediterranee Infect, F-13005 Marseille, France
[2] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, Inst Rech Dev,Unite MEPHI Microbes Evolut Phylogen, F-13005 Marseille, France
[3] Ctr Hosp Univ Timone, AP HM, Serv Cardiol, F-13005 Marseille, France
[4] Aix Marseille Univ, Fac Sci Med & Paramed, C2VN, F-13005 Marseille, France
[5] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, VITROME,IRD, F-13005 Marseille, France
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 05期
关键词
COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; QTc interval; cardiac rhythm; safety; torsades de pointe; COMBINATION; THERAPY;
D O I
10.3390/medicina59050863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 +/- 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 +/- 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature
    Goldman, Jason D.
    Diaz, George
    Urba, Walter J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [42] Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review
    Nag, Kaushik
    Tripura, Kaushik
    Datta, Anjan
    Karmakar, Nabarun
    Singh, Manvi
    Singh, Meenu
    Singal, Kusum
    Pradhan, Pranita
    INDIAN JOURNAL OF COMMUNITY MEDICINE, 2024, 49 (01) : 22 - 27
  • [43] Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19
    Guzman-Prado, Yuli
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 130 : 162 - 163
  • [44] Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
    Fiolet, Thibault
    Guihur, Anthony
    Rebeaud, Mathieu Edouard
    Mulot, Matthieu
    Peiffer-Smadja, Nathan
    Mahamat-Saleh, Yahya
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (01) : 138 - 140
  • [45] No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France"
    Lebeaux, David
    Revest, Matthieu
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 36
  • [46] Hydroxychloroquine and azithromycin: cardiovascular risk QTc prolongation and sudden death in the new COVID-19 outbreak
    Barjal, Luis D.
    Fitz Maurice, Mario
    Chavez Gonzalez, C. Elibet
    CORSALUD, 2020, 12 (01): : 54 - 59
  • [47] Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
    Cavalcanti, A. B.
    Zampieri, F. G.
    Rosa, R. G.
    Azevedo, L. C. P.
    Veiga, V. C.
    Avezum, A.
    Damiani, L. P.
    Marcadenti, A.
    Kawano-Dourado, L.
    Lisboa, T.
    Junqueira, D. L. M.
    de Barros e Silva, P. G. M.
    Tramujas, L.
    Abreu-Silva, E. O.
    Laranjeira, L. N.
    Soares, A. T.
    Echenique, L. S.
    Pereira, A. J.
    Freitas, F. G. R.
    Gebara, O. C. E.
    Dantas, V. C. S.
    Furtado, R. H. M.
    Milan, E. P.
    Golin, N. A.
    Cardoso, F. F.
    Maia, I. S.
    Hoffmann Filho, C. R.
    Kormann, A. P. M.
    Amazonas, R. B.
    Bocchi de Oliveira, M. F.
    Serpa-Neto, A.
    Falavigna, M.
    Lopes, R. D.
    Machado, F. R.
    Berwanger, O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21): : 2041 - 2052
  • [48] Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
    Mori, Nobuaki
    Katayama, Mitsuya
    Nukaga, Shigenari
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (01) : 109 - 112
  • [49] Electrocardiograms of a COVID-19 patient treated with the combination of hydroxychloroquine and azithromycin
    Benouna, Mohamed Elghali
    Ech-Chenbouli, Amine
    PAN AFRICAN MEDICAL JOURNAL, 2020, 35
  • [50] Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19
    Xu, Jiuyang
    Cao, Bin
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (01)